SHUKRA PHARMACEUTICALS L vs SUN PHARMACEUTICAL IND L

A side-by-side comparison of SHUKRA PHARMACEUTICALS L (SHUKRAPHAR) and SUN PHARMACEUTICAL IND L (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, SUN PHARMACEUTICAL IND L leads SHUKRAPHAR vs SUNPHARMA on 8 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

  • Valuation04
  • Profitability40
  • Growth11
  • Size & financial health13
ValueReturnsMarginGrowthScaleLow debt

Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.

Valuation

SUNPHARMA takes 4/4

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

236.36
P/E ratio
39.69
20.26
P/B ratio
20.07
0.02%
Dividend yield
0.84%
₹0.22
EPS
₹47.84

Profitability

SHUKRAPHAR takes 4/4

How efficiently each company turns capital and sales into profit. Higher is better.

28.90%
Return on equity
16.00%
22.00%
Return on capital
21.00%
39.00%
EBITDA margin
30.00%
30.30%
Net margin
19.69%

Growth

Even

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

-1.31%
Revenue CAGR (3Y)
10.03%
70.51%
Profit CAGR (3Y)
10.57%

Size & financial health

SUNPHARMA takes 3/4

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹369 Cr
Market cap
₹4.56L Cr
₹33 Cr
Revenue
₹58,462 Cr
₹10 Cr
Net profit
₹11,509 Cr
0.06
Debt / equity
0.61
SHUKRA PHARMACEUTICALS L
  • + ["Company is almost debt free.", "Company is expected to give good quarter", "Company has delivered good profit growth of 175% CAGR over last 5 years", "Company has a good return on equity (ROE) track record: 3 Years ROE 28.2%"]
  • ["Stock is trading at 21.6 times its book value", "Debtor days have increased from 122 to 148 days."]
SUN PHARMACEUTICAL IND L
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
SHUKRA PHARMACEUTICALS L full analysis SUN PHARMACEUTICAL IND L full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

SHUKRAPHAR vs SUNPHARMA: Share Price, Valuation & Which to Buy | DocStoX